Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of GensSci098 in Subjects With Graves' Disease
Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.
Summary
To evaluate the safety and tolerability of single ascending subcutaneous doses of GenSci098 in patients with Graves' Disease
Official title: A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Subcutaneous Dose of GenSci098 in Patients With Graves' Disease
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
24
Start Date
2025-11-21
Completion Date
2027-03-18
Last Updated
2026-02-17
Healthy Volunteers
No
Interventions
GenSci098
* Administration: Only one dose of GenSci098 will be given. * Route of Administration: Subcutaneous (injected under the skin). * Dose Levels: • Dose 1 • Dose 2• Dose 3• Dose 4
Locations (1)
The First Affiliated Hospital of China Medical University
Shenyang, Liaoning, China